Skip to main content
SpringerLink
Log in

The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis

  • Review Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Chemokines exert their multifunctional role in several physiologic and pathologic processes through interaction with their specific receptors. Much evidence have revealed that metastatic spread tumor cells may use chemokinemediated mechanisms. In particular, an involvement of stromal cell-derived factor-1 (SDF-1) in growth of primary tumors and in metastatic process has been demonstrated. Indeed, it has been suggested that CXCR4 expression by tumor cells, plays a critical role in cell metastasis by a chemotactic gradient to organs expressing the ligand SDF-1. Moreover, CXCR4 overexpression correlated with poor prognosis in many types of cancer. In physiologic condition, SDF-1 also plays an essential role modulating stem cell proliferation, survival, and homing through its canonical receptor CXCR4. Recently, several studies have demonstrated the existence of a small subset of cancer cells which share many characteristics with stem cells and named cancer stem cells (CSC). They constitute a reservoir of self-sustaining cells with the ability to maintain the tumor growth. In particular, most of them express CXCR4 receptor and respond to a chemotactic gradient of its specific ligand SDF-1, suggesting that CSC probably represent a subpopulation capable of initiating metastasis. This review focuses on the role of SDF-1/CXCR4 axis in cancer and in the metastatic progression by tumoral cells, as well as the role of CSC in tumor pathogenesis and in metastatic process. A better understanding of migratory mechanism involving cancer cells and CSC provides a powerful tool for developing novel therapies reducing both local and distant recurrences.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 2006, 42: 768–78.

    PubMed  CAS  Google Scholar 

  2. Schier AF. Chemokine signaling: rules of attraction. Curr Biol 2003, 13: R192–4.

    PubMed  CAS  Google Scholar 

  3. Broxmeyer HE, Cooper S, Kohli L, et al. Transgenic expression of stromal cell-derived factor-1/CXC chemokine ligand 12 enhances myeloid progenitor cell survival/ antiapoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo. J Immunol 2003, 170: 421–9.

    PubMed  CAS  Google Scholar 

  4. Horuk R. Chemokine receptors. Cytokine Growth Factor Rev 2001, 12: 313–35.

    PubMed  CAS  Google Scholar 

  5. Wang J, Shiozawa Y, Wang J, et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008, 283: 4283–94.

    PubMed  CAS  Google Scholar 

  6. Kucia M, Ratajczak J, Reca R, Janowska-Wieczorek A, Ratajczak MZ. Tissue-specific muscle, neural and liver stem/progenitor cells reside in the bone marrow, respond to an SDF-1 gradient and are mobilized into peripheral blood during stress and tissue injury. Blood Cells Mol Dis 2004, 32: 52–7.

    PubMed  CAS  Google Scholar 

  7. Kucia M, Reca R, Miekus K, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005, 23: 879–94.

    PubMed  CAS  Google Scholar 

  8. Burns JM, Summers BC, Wang Y, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J ExpMed 2006, 203: 2201–13.

    CAS  Google Scholar 

  9. Ben-Baruch A. Organ selectivity in metastasis: regulation of chemokines and their receptors. Clin Exp Metastasis 2007, Sep 21 [Epub ahead of print]; doi: 10.1007/s10585-007-9097-3.

  10. Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I. Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci 2007, 98: 1652–8.

    PubMed  CAS  Google Scholar 

  11. Tanaka K, Bai Z, Srinoulprasert Y, Yang BG, Hayasaka H, Miyasaka M. Chemokines in tumor progression and metastasis. Cancer Sci 2005, 96: 317–22.

    PubMed  CAS  Google Scholar 

  12. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410: 50–6.

    PubMed  Google Scholar 

  13. Koizumi K, Kozawa Y, Ohashi Y, et al. CCL21 promotes the migration and adhesion of highly lymph node metastatic human nonsmall cell lung cancer Lu-99 in vitro. Oncol Rep 2007, 17: 1511–6.

    PubMed  CAS  Google Scholar 

  14. Kakinuma T, Hwang ST. Chemokines, chemokine receptors, and cancer metastasis. J Leukocyte Biol 2006, 79: 639–50.

    PubMed  CAS  Google Scholar 

  15. Morales J, Homey B, Vicari AP, et al. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memoty T cells. Proc Natl Acad Sci U S A 1999, 96: 14470–5.

    PubMed Central  PubMed  CAS  Google Scholar 

  16. Murakami T, Cardones AR, Finkelstein SE, et al. Immune evasion by murine melanoma mediated trough CC chemokine receptor-10. J Exp Med 2003, 198: 1337–47.

    PubMed Central  PubMed  CAS  Google Scholar 

  17. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 17, 367: 645–8.

    Google Scholar 

  18. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100: 3983–8.

    PubMed Central  PubMed  CAS  Google Scholar 

  19. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004, 432: 396–401.

    PubMed  CAS  Google Scholar 

  20. Bagri A, Gurney T, He X, et al. The chemokine SDF1 regulates migration of dentate granule cells. Development2002, 129: 4249–60.

    PubMed  CAS  Google Scholar 

  21. Kryczek I, Wei S, Keller E, Liu R, Zou W. Stroma-derived factor (SDF1 /CXCL12) and human pathogenesis. Am J Physiol Cell Physiol 2007, 292: C987–95.

    PubMed  CAS  Google Scholar 

  22. Grunewald M, Avraham I, Dor Y, et al. VEGF-induced adult neovascularisation: recruitment, retention, and role of accessory cells. Cell 2006, 124: 175–89.

    PubMed  CAS  Google Scholar 

  23. Katayama Y, Battista M, Kao WM, et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell 2006, 124: 407–21.

    PubMed  CAS  Google Scholar 

  24. Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bon marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002, 3: 687–94.

    PubMed  CAS  Google Scholar 

  25. Ponomaryov T, Peled A, Petit I, et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 2000, 106: 1331–9.

    PubMed Central  PubMed  CAS  Google Scholar 

  26. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in hematopoiesis and in cerebellar development. Nature 1998, 393: 595–9.

    PubMed  CAS  Google Scholar 

  27. Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR. Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res 2001, 61: 4961–5.

    PubMed  CAS  Google Scholar 

  28. Phillips RJ, Burdick MD, Lutz M, et al. The stromal derived factor 1/CXCL1 2/CXC chemokine receptor 4 biological axis in nonsmall cell lung cancer. Am J Respir Crit Care Med 2003, 167: 1676–86.

    PubMed  Google Scholar 

  29. Katayama A, Ogino T, Bandoh N, Nonaka S, Harabuchi Y. Expression of CXCR4 and its down-regulation by IFN-gamma in head and neck squamous cell carcinoma. Clin Cancer Res 2005, 11: 2937–46.

    PubMed  CAS  Google Scholar 

  30. Marchesi F, Monti P, Leone BE, et al. Increased survival, proliferatio and migration in human pancreatic tumor cells expressing functional CXCR4. Cancer Res 2004, 64: 8420–7.

    PubMed  CAS  Google Scholar 

  31. Helbig G, Christopherson KW 2nd, Bhat-Nakshatri P, et al. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003, 278: 21631–8.

    PubMed  CAS  Google Scholar 

  32. Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 2005, 24: 4462–71.

    PubMed  CAS  Google Scholar 

  33. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002, 62: 1832–7.

    PubMed  CAS  Google Scholar 

  34. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121: 335–48.

    PubMed  CAS  Google Scholar 

  35. Salcedo R, Wasserman K, Young HA, et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol 1999, 154: 1125–35.

    PubMed Central  PubMed  CAS  Google Scholar 

  36. Kryczek I, Lange A, Mottram P, et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 2005, 65: 465–72.

    PubMed  CAS  Google Scholar 

  37. Darash-Yahana M, Pikarsky E, Abramovitch R, et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 2004, 18: 1240–2.

    PubMed  CAS  Google Scholar 

  38. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004, 10: 858–64.

    PubMed  CAS  Google Scholar 

  39. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003, 425: 307–11.

    PubMed  CAS  Google Scholar 

  40. Schioppa T, Uranchimeg B, Saccani A, et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003, 198: 1391–402.

    PubMed Central  PubMed  CAS  Google Scholar 

  41. Guleng B, Tateishi K, Ohta M, et al. Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res 2005, 65: 5864–71.

    PubMed  CAS  Google Scholar 

  42. Wendt MK, Johanesen PA, Kang-Decker N, Binion DG, Shah V, Dwinell MB. Silencing of epithelial CXCL12 expression by DNA hypermethylation promotes colonic carcinoma metastasis. Oncogene 2006, 25: 4986–97.

    PubMed  CAS  Google Scholar 

  43. Zeelenberg IS, Ruuls-Van Stalle S, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 2003, 63: 3833–9.

    PubMed  CAS  Google Scholar 

  44. Sun YX, Schneider A, Jung Y, et al. Skeletal localisation and neutralisation of SDF1 (CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseus sites in vivo. J Bone Miner Res 2005, 20: 318–29.

    PubMed  CAS  Google Scholar 

  45. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272: 872–7.

    PubMed  CAS  Google Scholar 

  46. Khan A, Greenman J, Archibald SJ. Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates. Curr Med Chem 2007, 14: 2257–77.

    PubMed  CAS  Google Scholar 

  47. Raggo C, Ruhl R, McAllister S, et al. Novel cellular genes essential for transformation of endothelial cells by Kaposi’s sarcoma-associated herpes virus. Cancer Res 2005, 65: 5084–95.

    PubMed  CAS  Google Scholar 

  48. Miao Z, Luker KE, Summers BC, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumorassociated vasculature. Proc Natl Acad Sci U S A 2007, 104: 15735–40.

    PubMed Central  PubMed  CAS  Google Scholar 

  49. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004, 4: 540–50.

    PubMed  CAS  Google Scholar 

  50. Kim J, Takeuchi H, Lam ST, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 2005, 23: 2744–53.

    PubMed  CAS  Google Scholar 

  51. Longo-Imedio MI, Longo N, Treviño I, Lázaro P, Sánchez-Mateos P. Clinical significance of CXCR3 and CXCR4 expression in primary melanoma. Int J Cancer 2005, 117: 861–5.

    PubMed  CAS  Google Scholar 

  52. Scala S, Ottaiano A, Ascierto PA, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005, 11: 1835–41.

    PubMed  CAS  Google Scholar 

  53. Kato M, Kitayama J, Kazama S, Nagawa H. Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res 2003, 5: R144–50.

    PubMed Central  PubMed  CAS  Google Scholar 

  54. Li YM, Pan Y, Wei Y, et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004, 6: 459–69; comment: 429–30.

    PubMed  CAS  Google Scholar 

  55. Rombouts EJ, Pavic B, Löwenberg B, Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004, 104: 550–7.

    PubMed  CAS  Google Scholar 

  56. Spano JP, Andre F, Morat L, et al. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol 2004, 15: 613–7.

    PubMed  Google Scholar 

  57. Sun YX, Fang M, Wang J, Cooper CR, Pienta KJ, Taichman RS. Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate 2007, 67: 61–73.

    PubMed  CAS  Google Scholar 

  58. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 2008, 122: 91–9.

    PubMed  CAS  Google Scholar 

  59. De Falco V, Guarino V, Avilla E, et al. Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Res 2007, 67: 11821–9.

    PubMed  Google Scholar 

  60. Bian XW, Yang SX, Chen JH, et al. Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival. Neurosurgery 2007, 61: 570–8.

    PubMed  Google Scholar 

  61. Gockel I, Schimanski CC, Heinrich C, et al. Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma. BMC Cancer 2006, 6: 290.

    PubMed Central  PubMed  Google Scholar 

  62. Kodama J, Hasengaowa, Kusumoto T, et al. Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer. Ann Oncol 2007, 18: 70–6.

    PubMed  CAS  Google Scholar 

  63. Oda Y, Yamamoto H, Tamiya S, et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol 2006, 19: 738–45.

    PubMed  CAS  Google Scholar 

  64. Shen W, Bendall LJ, Gottlieb DJ, Bradstock KF. The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow. Exp Hematol 2001, 29: 1439–47.

    PubMed  CAS  Google Scholar 

  65. Tavor S, Petit I, Porozov S, et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 2004, 64: 2817–24.

    PubMed  CAS  Google Scholar 

  66. Cardones AR, Murakami T, Hwang ST. CXCR4 enhances adhesion of B16 to endothelial cells tumor cells in vitro and in vivo via beta(1) integrin. Cancer Res 2003, 63: 6751–7.

    PubMed  CAS  Google Scholar 

  67. Engl T, Relja B, Marian D, et al. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia 2006, 8: 290–301.

    PubMed Central  PubMed  CAS  Google Scholar 

  68. Jiang YP, Wu XH, Xing HY, DU XY. Role of CXCL12 in metastasis of human ovarian cancer. Chin Med J (Engl) 2007, 120: 1251–5.

    CAS  Google Scholar 

  69. Engl T, Relja B, Blumenberg C, et al. Prostate tumor CXCchemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci 2006, 78: 1784–93.

    PubMed  CAS  Google Scholar 

  70. Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003, 89: 1817–21.

    PubMed Central  PubMed  CAS  Google Scholar 

  71. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002, 62: 1832–7.

    PubMed  CAS  Google Scholar 

  72. Chinni SR, Sivalogan S, Dong Z, et al. CXCL1 2/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 2006, 66: 32–48.

    PubMed  CAS  Google Scholar 

  73. Singh S, Singh UP, Grizzle WE, Lillard JW Jr. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest 2004, 84: 1666–76.

    PubMed  CAS  Google Scholar 

  74. Yuecheng Y, Xiaoyan X. Stromal-cell derived factor-1 regulates epithelial ovarian cancer cell invasion by activating matrix metalloproteinase-9 and matrix metalloproteinase-2. Eur J Cancer Prev 2007, 16: 430–5.

    PubMed  Google Scholar 

  75. Hall JM, Korach KS. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol 2003, 17: 792–803.

    PubMed  CAS  Google Scholar 

  76. Porcile C, Bajetto A, Barbieri F, et al. Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Exp Cell Res 2005, 308: 241–53.

    PubMed  CAS  Google Scholar 

  77. Pattarozzi A, Gatti M, Barbieri F, et al. 17beta-estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment. Mol Pharmacol 2008, 73: 191–202.

    PubMed  CAS  Google Scholar 

  78. Cabioglu N, Summy J, Miller C, et al. CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 2005, 65: 6493–7.

    PubMed  CAS  Google Scholar 

  79. Khazaie K, Schirrmacher V, Lichtner RB. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 1993, 12: 255–74.

    PubMed  CAS  Google Scholar 

  80. Ménard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E. Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci 2004, 61: 2965–78.

    PubMed  Google Scholar 

  81. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2: 127–37.

    PubMed  CAS  Google Scholar 

  82. Callewaere C, Banisadr G, Desarménien MG, et al. The chemokine SDF-1/CXCL12 modulates the firing pattern of vasopressin neurons and counteracts induced vasopressin release through CXCR4. Proc Natl Acad Sci U S A 2006, 103: 8221–6.

    PubMed Central  PubMed  CAS  Google Scholar 

  83. Florio T, Casagrande S, Diana F, et al. Chemokine stromal cell-derived factor 1alpha induces proliferation and growth hormone release in GH4C1 rat pituitary adenoma cell line through multiple intracellular signals. Mol Pharmacol 2006, 69: 539–46.

    PubMed  CAS  Google Scholar 

  84. Barbieri F, Bajetto A, Porcile C, Pattarozzi A, Schettini G, Florio T. Role of stromal cell-derived factor 1 (SDF1/CXCL12) in regulating anterior pituitary function. J Mol Endocrinol 2007, 38: 383–9.

    PubMed  CAS  Google Scholar 

  85. Castellone MD, Guarino V, De Falco V, et al. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene 2004, 23: 5958–67.

    PubMed  CAS  Google Scholar 

  86. Hwang JH, Hwang JH, Chung HK, et al. CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2003, 88: 408–16.

    PubMed  CAS  Google Scholar 

  87. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stemcell biology to cancer. Nat Rev Cancer 2003, 3: 895–902.

    PubMed  CAS  Google Scholar 

  88. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001, 414: 105–11.

    PubMed  CAS  Google Scholar 

  89. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006, 66: 9339–44.

    PubMed  CAS  Google Scholar 

  90. Lapidot T, Pflumio F, Doedens M, Murdoch B, Williams DE, Dick JE. Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in SCID mice. Science 1992, 255: 1137–41.

    PubMed  CAS  Google Scholar 

  91. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63: 5821–8.

    PubMed  CAS  Google Scholar 

  92. Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene 2004, 23: 7267–73.

    PubMed  CAS  Google Scholar 

  93. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS. Stem cells in normal breast development and breast cancer. Cell Prolif 2003, 36 (Suppl 1): 59–72.

    PubMed  CAS  Google Scholar 

  94. Xin L, Lawson DA, Witte ON. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci U S A 2005, 102: 6942–7.

    PubMed Central  PubMed  CAS  Google Scholar 

  95. Burger PE, Xiong X, Coetzee S, et al. Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. Proc Natl Acad Sci U S A 2005, 102: 7180–5.

    PubMed Central  PubMed  CAS  Google Scholar 

  96. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65: 10946–51.

    PubMed  CAS  Google Scholar 

  97. Kim CF, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005, 121: 823–35.

    PubMed  CAS  Google Scholar 

  98. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 2003, 100: 15178–83.

    PubMed Central  PubMed  CAS  Google Scholar 

  99. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004, 64: 7011–21.

    PubMed  CAS  Google Scholar 

  100. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445: 111–5.

    PubMed  CAS  Google Scholar 

  101. O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445: 106–10.

    PubMed  Google Scholar 

  102. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65: 10946–51.

    PubMed  CAS  Google Scholar 

  103. Clarke MF. A self-renewal assay for cancer stem cells. Cancer Chemother Pharmacol 2005, 1: 64–8.

    Google Scholar 

  104. Wicha MS. Identification of murine mammary stem cells: implications for studies of mammary development and carcinogenesis. Breast Cancer Res 2006, 8: 109.

    PubMed Central  PubMed  Google Scholar 

  105. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L. Brca1 breast tumors contain distinct CD44+/CD24− and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 2008, 10: R10.

    PubMed Central  PubMed  Google Scholar 

  106. Petersen OW, Høyer PE, van Deurs B. Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. Cancer Res 1987, 47: 5748–51.

    PubMed  CAS  Google Scholar 

  107. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997, 57: 4987–91.

    PubMed  CAS  Google Scholar 

  108. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci U S A 2004, 101: 781–6.

    PubMed Central  PubMed  CAS  Google Scholar 

  109. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2− cancer cells are similarly tumorigenic. Cancer Res 2005, 65: 6207–19.

    PubMed  CAS  Google Scholar 

  110. Chiba T, Kita K, Zheng YW, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006, 44: 240–51.

    PubMed  CAS  Google Scholar 

  111. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A 2006, 103: 11154–9.

    PubMed Central  PubMed  CAS  Google Scholar 

  112. Mitsutake N, Iwao A, Nagai K, et al. characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively. Endocrinology 2007, 148: 1797–803.

    PubMed  CAS  Google Scholar 

  113. Zhang P, Zuo H, Ozaki T, Nakagomi N, Kakudo K. Cancer stem cell hypothesis in thyroid cancer. Pathol Int 2006, 56: 485–9.

    PubMed  CAS  Google Scholar 

  114. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer 1997, 80: 1529–37.

    PubMed  CAS  Google Scholar 

  115. Yang AD, Camp ER, Fan F, et al. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res 2006, 66: 46–51.

    PubMed  CAS  Google Scholar 

  116. Christofori G. New signals from the invasive front. Nature 2006, 441: 444–50.

    PubMed  CAS  Google Scholar 

  117. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004, 14: 171–9.

    PubMed  CAS  Google Scholar 

  118. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006, 6: 392–401.

    PubMed  CAS  Google Scholar 

  119. Wai PY, Kuo PC. The role of Osteopontin in tumor metastasis. J Surg Res 2004, 121: 228–41.

    PubMed  CAS  Google Scholar 

  120. Gazitt Y. Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatment with chemotherapy and antilineage-specific antibodies. Leukemia 2004, 18: 1–10.

    PubMed  CAS  Google Scholar 

  121. Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002, 30: 973–81.

    PubMed  CAS  Google Scholar 

  122. Hattori K, Heissig B, Tashiro K, et al. Plasma elevation of stromal cellderived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 2001, 97: 3354–60.

    PubMed  CAS  Google Scholar 

  123. Kucia M, Ratajczak J, Ratajczak MZ. Bone marrow as a source of circulating CXCR4+ tissue committed stem cells. Biol Cell 2005, 97: 133–46.

    PubMed  CAS  Google Scholar 

  124. Korbling M, Estrov Z. Adult stem cells for tissue repair — a new therapeutic concept? N Engl J Med 2003, 349: 570–82.

    PubMed  Google Scholar 

  125. Kucia M, Reca R, Jala VR, Dawn B, Ratajczak J, Ratajczak MZ. Bone marrow as a home of heterogenous populations of non-hematopoietic stem cells. Leukemia 2005, 19: 1118–27.

    PubMed  CAS  Google Scholar 

  126. Kucia M, Dawn B, Hunt G, et al. Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarction. Circ Res 2004, 95: 1191–9.

    PubMed Central  PubMed  CAS  Google Scholar 

  127. Wojakowski W, Tendera M, Michałowska A, et al. Mobilization of CD34/CXCR4+, CD34/CD117 +, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation 2004, 110: 3213–20.

    PubMed  CAS  Google Scholar 

  128. Kucia M, Zhang YP, Reca R, et al. Cells enriched in markers of neural tissue-committed stem cells reside in the bone marrow and are mobilized into the peripheral blood following stroke. Leukemia 2006, 20: 18–28.

    PubMed  CAS  Google Scholar 

  129. Paczkowska E, Larysz B, Rzeuski R, et al. Human hematopoietic stem/progenitor-enriched CD34(+) cells are mobilized into peripheral blood during stress related to ischemic stroke or acute myocardial infarction. Eur J Haematol 2005, 75: 461–7.

    PubMed  CAS  Google Scholar 

  130. Petersen BE, Bowen WC, Patrene KD, et al. Bone marrow as a potential source of hepatic oval cells. Science 1999, 284: 1168–70.

    PubMed  CAS  Google Scholar 

  131. Togel F, Isaac J, Hu Z, Weiss K, Westenfelder C. Renal SDF-1 signals mobilization and homing of CXCR4-positive cells to the kidney after ischemic injury. Kidney Int 2005, 67: 1772–84.

    PubMed  Google Scholar 

  132. Kale S, Karihaloo A, Clark PR, Kashgarian M, Krause DS, Cantley LG. Bone marrow stem cells contribute to repair of the ischemically injured renal tubule. J Clin Invest 2003, 112: 42–9.

    PubMed Central  PubMed  CAS  Google Scholar 

  133. Hess D, Li L, Martin M, et al. Bone marrow-derived stem cells initiate pancreatic regeneration. Nat Biotechnol 2003, 21: 763–70.

    PubMed  CAS  Google Scholar 

  134. Long MA, Corbel SY, Rossi FM. Circulating myogenic progenitors and muscle repair. Semin Cell Dev Biol 2005, 16: 632–40.

    PubMed  CAS  Google Scholar 

  135. Sata M, Tanaka K, Nagai R. Circulating osteoblast-lineage cells. N Engl J Med 2005, 353: 737–8.

    PubMed  CAS  Google Scholar 

  136. Gomperts BN, Belperio JA, Rao PN, et al. Circulating progenitor epithelial cells traffic via CXCR4/CXCL12 in response to airway injury. J Immunol 2006, 176: 1916–27.

    PubMed  CAS  Google Scholar 

  137. Mazzinghi B, Ronconi E, Lazzeri E, et al. Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. J Exp Med 2008, 205: 479–90.

    PubMed Central  PubMed  CAS  Google Scholar 

  138. Nagasawa T, Hirota S, Tachibana K et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996, 382: 635–8.

    PubMed  CAS  Google Scholar 

  139. Ma Q, Jones D, Springer TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 1999, 10: 463–71.

    PubMed  CAS  Google Scholar 

  140. Geminder H, Sagi-Assif O, Goldberg L, et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 2001, 167: 4747–57.

    PubMed  CAS  Google Scholar 

  141. Porcile C, Bajetto A, Barbero S, Pirani P, Schettini G. CXCR4 activation induces epidermal growth factor receptor transactivation in an ovarian cancer cell line. Ann N Y Acad Sci 2004, 1030: 162–9.

    PubMed  CAS  Google Scholar 

  142. Libura J, Drukala J, Majka M, et al. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood 2002, 100: 2597–606.

    PubMed  CAS  Google Scholar 

  143. Jankowski K, Kucia M, Wysoczynski M, et al. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res 2003, 63: 7926–35.

    PubMed  CAS  Google Scholar 

  144. Peled A, PetitI, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999, 283: 845–8.

    PubMed  CAS  Google Scholar 

  145. Peled A, Kollet O, Ponomaryov T, et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 2000, 95: 3289–96.

    PubMed  CAS  Google Scholar 

  146. Peled A, Grabovsky V, Habler L, et al. The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow. J Clin Invest 1999, 104: 1199–211.

    PubMed Central  PubMed  CAS  Google Scholar 

  147. Janowska-Wieczorek A, Marquez LA, Dobrowsky A, Ratajczak MZ, Cabuhat ML. Differential MMP and TIMP production by human marrow and peripheral blood CD34(+) cells in response to chemokines. Exp Hematol 2000, 28: 1274–85.

    PubMed  CAS  Google Scholar 

  148. Kijowski J, Baj-Krzyworzeka M, Majka M, et al. The SDF-1-CXCR4 axis stimulates VEGF secretion and activates integrins butdoes not affect proliferation and survival in lymphohematopoietic cells. Stem Cells 2001, 19: 453–66.

    PubMed  CAS  Google Scholar 

  149. Burger JA, Spoo A, Dwenger A, Burger M, Behringer D. CXCR4 chemokine receptors (CD184) and alpha4beta1 integrins mediate spontaneous migration of human CD34+progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis). Br J Haematol 2003, 122: 579–89.

    PubMed  CAS  Google Scholar 

  150. Peled A, Hardan I, Trakhtenbrot L, et al. Immature leukemic CD34+ CXCR4+ cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1. Stem Cells 2002, 20: 259–66.

    PubMed  CAS  Google Scholar 

  151. Cashman J, Clark-Lewis I, Eaves A, Eaves C. Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. Blood 2002, 99: 792–9.

    PubMed  CAS  Google Scholar 

  152. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438: 820–7.

    PubMed Central  PubMed  CAS  Google Scholar 

  153. Kaplan RN, Psaila B, Lyden D. Niche-to-niche migration of bonemarrow-derived cells. Trends Mol Med 2007, 13: 72–81.

    PubMed  CAS  Google Scholar 

  154. Scadden DT. The stem-cell niche as an entity of action. Nature 2006, 441: 1075–9.

    PubMed  CAS  Google Scholar 

  155. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res 2006, 66: 4553–7.

    PubMed  CAS  Google Scholar 

  156. Zou W. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat Rev Cancer 2005, 5: 263–74.

    PubMed  CAS  Google Scholar 

  157. Esté JA, Telenti A. HIV entry inhibitors. Lancet 2007, 370: 81–8.

    PubMed  Google Scholar 

  158. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II doseescalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003, 30: 117–24.

    PubMed  CAS  Google Scholar 

  159. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350: 2335–42.

    PubMed  CAS  Google Scholar 

  160. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomixed trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21: 60–5.

    PubMed  CAS  Google Scholar 

  161. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349: 427–34.

    PubMed Central  PubMed  CAS  Google Scholar 

  162. Sato N, Matsubayashi H, Fukushima N, Goggins M. The chemokine receptor CXCR4 is regulated by DNA, methylation in pancreatic cancer. Cancer Biol Ter 2005, 4: 70–6.

    CAS  Google Scholar 

  163. Mori T, Kim J, Yamano T, et al. Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. Cancer Res 2005, 65: 1800–7.

    PubMed  CAS  Google Scholar 

  164. Kubarek Ł, Jagodzinski PP. Epigenetic upregulation of CXCR4 and CXCL12 expression by 17 beta-estradiol and tamoxifen is associated with formation of DNAmethyltransferase 3B4 slpice variantin Ishikawa endometrial adenocarcinoma cells. FEBS Lett 2007, 58: 1441–8.

    Google Scholar 

  165. Sowi ska A, Jagodzinski PP. RNA interference-mediated knockdown of DNMT1 and DNMT3B induces CXCL12 expression in MCF-7 breast cancer and AsPC1 pancreatic carcinoma cell lines. Cancer Lett 2007, 255: 153–9.

    Google Scholar 

  166. Kelly WK, O’Connor OA, Marks PA. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs 2002, 11: 1695–713.

    PubMed  CAS  Google Scholar 

  167. Dahl C, Guldberg P. High resolution melting for accurate assessment of DNA methylation. Clinical Chem 2007, 53: 1877–8.

    CAS  Google Scholar 

  168. Bai S, Jain MK, Berg OG. Contiguous binding of decylsulfate on the interface-binding surface of pancreatic phospholipase A2. Biochemistry 2008, Feb 8 [Epub ahead of print]; doi: 10.1021/bi702164n.

  169. Mund C, Hackanson B, Stresemann C, Lübbert M, Lyko F. Characterization of DNA demethylation effects induced by 5-Aza-2’-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res 2005, 65: 7086–90.

    PubMed  CAS  Google Scholar 

  170. Müller CI, Rüter B, Koeffler HP, Lübbert M. DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AML.Curr Pharm Biotechnol 2006, 7: 315–21.

    PubMed  Google Scholar 

  171. Leone G, Voso MT, Teofili L, Lübbert M. Inhibitors od DNA methylation in the treatment of haematological malignancies and MDS. Clin Immunol 2003, 109: 89–102.

    PubMed  CAS  Google Scholar 

  172. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003, 102: 2728–30.

    PubMed  CAS  Google Scholar 

  173. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin’s lymphoma. J Clin Oncol 2004, 22: 1095–102.

    PubMed  CAS  Google Scholar 

  174. Kirsch C, Eckert GP, Mueller WE. Statin effects on cholesterol microdomains in brain plasma membranes. Biochem Pharmacol 2003, 65: 843–56.

    PubMed  CAS  Google Scholar 

  175. Chen Y, Stamatoyannopoulos G, Song CZ. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res 2003, 63: 4801–4.

    PubMed  CAS  Google Scholar 

  176. Mazure NM, Brahimi-Horn MC, Berta MA, et al. HIF-1: master and commander of the hypoxic world. Apharmacological approach to its regulation by siRNAs. Biochem Pharmacol 2004, 68: 971–80.

    PubMed  CAS  Google Scholar 

  177. Kung AL, Zabludoff SD, France DS, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 2004, 6: 33–43.

    PubMed  CAS  Google Scholar 

  178. Christopherson KW 2nd, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004, 305: 1000–3.

    PubMed  CAS  Google Scholar 

  179. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005, 115: 959–68.

    PubMed Central  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Biochemistry Unit, University of Florence, Florence, Italy

    S. Gelmini

  2. Radiotherapy Unit, University of Florence, Florence, Italy

    M. Mangoni

  3. Endocrinology Unit, Department of Clinical Pathophysiology, University of Florence, Florence, Italy

    M. Serio

  4. Excellence Center for Research, Transfer and High Education DENOthe, University of Florence, Florence, Italy

    P. Romagnani & E. Lazzeri PhD

Authors
  1. S. Gelmini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Mangoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Serio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Romagnani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Lazzeri PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Lazzeri PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gelmini, S., Mangoni, M., Serio, M. et al. The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis. J Endocrinol Invest 31, 809–819 (2008). https://doi.org/10.1007/BF03349262

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03349262

Key-words

Search

Navigation